https://www.selleckchem.com/pr....oducts/Vorinostat-sa
g., atorvastatin, alprazolam, salmeterol, and tamsulosin). Ischemic heart disease, chronic respiratory diseases, and ICU admission were significantly associated with the occurrence of pDDIs. We recommend considering the risk factors for the emergence of clinically important DDIs in the pharmacotherapy of COVID-19 patients. Using an alternative medication or dose adjustments may be required in high-risk patients. We recommend considering the risk factors for the emergence of clinically important DDIs in the pharmacotherapy of COV
Tycka om
Kommentar
Dela med sig
